Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Innoviva Inc (INVA)

Innoviva Inc (INVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,265,775
  • Shares Outstanding, K 101,262
  • Annual Sales, $ 261,000 K
  • Annual Income, $ 395,060 K
  • 60-Month Beta 1.45
  • Price/Sales 4.73
  • Price/Cash Flow 2.96
  • Price/Book 4.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Sell
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.60
  • Number of Estimates 1
  • High Estimate 0.60
  • Low Estimate 0.60
  • Prior Year 2.34
  • Growth Rate Est. (year over year) -74.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.50 +16.38%
on 10/24/19
12.51 -2.32%
on 11/08/19
+1.56 (+14.63%)
since 10/11/19
3-Month
10.03 +21.83%
on 09/26/19
12.51 -2.32%
on 11/08/19
+0.79 (+6.91%)
since 08/09/19
52-Week
10.03 +21.83%
on 09/26/19
20.54 -40.51%
on 01/30/19
-4.17 (-25.44%)
since 11/09/18

Most Recent Stories

More News
Innoviva: 3Q Earnings Snapshot

BRISBANE, Calif. (AP) _ Innoviva Inc. (INVA) on Wednesday reported third-quarter net income of $39.8 million.

INVA : 12.22 (-2.24%)
Innoviva Reports Third Quarter 2019 Financial Results

Innoviva, Inc. (NASDAQ: INVA) (the "Company") today reported financial results for the third quarter ended September 30, 2019.

INVA : 12.22 (-2.24%)
Innoviva: 2Q Earnings Snapshot

BRISBANE, Calif. (AP) _ Innoviva Inc. (INVA) on Wednesday reported second-quarter earnings of $37.7 million.

INVA : 12.22 (-2.24%)
Moleculin Files New Patents for Cancer Candidate Annamycin

Moleculin (MBRX) petitions for new patents to cover annamycin, currently being developed for treating patients with relapsed or refractory acute myeloid leukemia. Shares rise.

INVA : 12.22 (-2.24%)
MRUS : 16.01 (+2.23%)
KDMN : 2.99 (-0.66%)
MBRX : 1.06 (-1.85%)
Earnings Estimates Moving Higher for Innoviva (INVA): Time to Buy?

Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

INVA : 12.22 (-2.24%)
New Strong Buy Stocks for May 15th

New Strong Buy Stocks for May 15th

NDLS : 5.95 (+5.12%)
INVA : 12.22 (-2.24%)
FET : 1.16 (-2.52%)
CLMT : 3.76 (+10.59%)
ASIX : 23.78 (-1.12%)
Market Trends Toward New Normal in lululemon athletica inc, Innoviva, aTyr Pharma, and Vivopower International Plc -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of lululemon athletica inc....

LULU : 207.19 (+1.50%)
INVA : 12.22 (-2.24%)
LIFE : 3.70 (-2.12%)
VVPR : 1.26 (-0.79%)
Phase III CAPTAIN Study of Trelegy Ellipta in Patients with Asthma Meets Primary Endpoint

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy...

GSK : 44.26 (-0.36%)
INVA : 12.22 (-2.24%)
Innoviva: 1Q Earnings Snapshot

BRISBANE, Calif. (AP) _ Innoviva Inc. (INVA) on Wednesday reported first-quarter profit of $33.8 million.

INVA : 12.22 (-2.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Soft.

See More Share

Trade INVA with:

Business Summary

Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance,...

See More

Key Turning Points

2nd Resistance Point 12.57
1st Resistance Point 12.40
Last Price 12.22
1st Support Level 12.10
2nd Support Level 11.97

See More

52-Week High 20.54
Fibonacci 61.8% 16.53
Fibonacci 50% 15.28
Fibonacci 38.2% 14.04
Last Price 12.22
52-Week Low 10.03

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar